Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Agenus. The associated price target remains the same with $23.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Emily Bodnar’s rating is based on the promising clinical trial results for Agenus’s botensilimab and balstilimab combination therapy. The Phase 1b trial demonstrated a significant median overall survival of 17.2 months in a late-line patient population, which is notably higher than the typical median overall survival of less than 12 months for such patients. Additionally, the trial showed a 39% two-year survival rate, indicating long-term efficacy across multiple solid tumor types.
Furthermore, the safety profile of the 1 mg/kg dose of botensilimab was favorable, with fewer severe adverse events compared to the higher dose. The trial also revealed that patients experiencing immune-mediated adverse events had better survival outcomes, highlighting the mechanism of action of the therapy. These factors suggest that the botensilimab and balstilimab combination could offer durable efficacy and a favorable risk-benefit profile, supporting the Buy rating for Agenus’s stock.